Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
We are dedicated to delivering first-in-class cancer cell directed therapies and boldly pursuing innovative strategies in immuno-oncology. We are also designing smart combinations with the goal of bringing benefit to patients. Find out more about how we’re taking cancer on through our oncology clinical trial programme.
Explore the videos and materials below to learn more about how Boehringer Ingelheim are taking cancer on.
Xentuzumab, BI 836858, BI 836880, BI 894999, BI 754091, BI754111, BI 891065, BI 907828, BI 905677, BI 765063 and BI 1361849 are investigational compounds and have not been approved. Their safety and efficacy have not been established.
© 2019 Boehringer Ingelheim International GmbH. All rights reserved.
Page last updated: May 2019
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue